International Journal of Internal Medicine. 2020; 1: (1) 6; DOI:10.12208/j.ijim.20200007.
Objective: To compare the clinical efficacy of tamoxifen and letrozole in the treatment of postmenopausal breast cancer and its influences on the blood lipid metabolism. Methods: 68 patients with postmenopausal breast cancer were randomly divided into two groups (n=34). The patients in group A were treated with tamoxifen and the patients in group B were treated with letrozole. Then compared the blood lipid metabolism, endometrial thickness, clinical efficacy and so on before and after treatment of two groups. Results: The levels of TC and LDL-C in group A were significantly decreased and HDL-C levels were significantly increased after treatment (P<0.05). There was no significant change in all the lipid metabolism parameters before and after treatment in group B (P>0.05). The levels of TC and LDL-C in group A after treatment were significantly lower than those in group B, and the level of HDL-C was significantly higher than that in group B (P<0.05). The thickness of endometrium in group A was significantly higher than that in group B after treatment one year and two years (P<0.05). The total incidence of endometrial hyperplasia in group A was significantly higher than that in group B, and the total effective rate was significantly lower than that in group B (P<0.05). Conclusion : Letrozole is superior to tamoxifen in the treatment of postmenopausal breast cancer, while reducing the thickness of endometrium and reducing the risk of endometrial lesions. Tamoxifen can effectively improve the blood lipid metabolism in patients.